LEP and neoplasm: Using different doses of recombinant leptin as well as a superactive mouse leptin antagonist (SMLA) that abrogates leptin’s signalling activity even when bound to LEPR30, we further found that circulating leptin accelerated tumour growth in a dose-dependent manner, whereas SMLA had a slightly repressive effect (Fig. 4g).